<DOC>
	<DOCNO>NCT01506167</DOCNO>
	<brief_summary>This prospective , multi-center , observational study ass safety efficacy Avastin ( bevacizumab ) daily practice patient metastatic colorectal cancer receive previous treatment advance disease receive Avastin combination standard care first-line chemotherapy regimen . Data collect 1.5 year death .</brief_summary>
	<brief_title>An Observational Study Avastin ( Bevacizumab ) Patients With Metastatic Colorectal Cancer ( ACORN )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Metastatic colorectal cancer previous systemic treatment advance disease Receiving Avastin combination firstline standard care chemotherapy regimen Avastin initiate time firstline chemotherapy regimen Investigational , nonstandard care firstline chemotherapy regimen treatment metastatic colorectal cancer Contraindication Avastin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>